Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer

Background: Based on current guidelines, clinical T3N0M0 esophageal tumors may or may not receive neoadjuvant treatment, according to their perception as locally advanced (cT3) or early-stage tumors (stage II). The study aim was to assess the impact of neoadjuvant treatment upon survival for cT3N0M0...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Mantziari, Styliani (author)
مؤلفون آخرون:	Gronnier, Caroline (author), Renaud, Florence (author), Duhamel, Alain (author), Théreaux, Jérémie (author), Brigand, Cécile (author), Carrère, Nicolas (author), Lefevre, Jérémie H. (author), Pasquer, Arnaud (author), Demartines, Nicolas (author), Collet, Denis (author), Meunier, Bernard (author), Mariette, Christophe (author)
التنسيق:	article
منشور في:	2017
الوصول للمادة أونلاين:	http://hdl.handle.net/10725/14208 https://doi.org/10.1097/SLA.0000000000002402 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://pubmed.ncbi.nlm.nih.gov/28742698/
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

الانترنت

http://hdl.handle.net/10725/14208
https://doi.org/10.1097/SLA.0000000000002402
http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php
https://pubmed.ncbi.nlm.nih.gov/28742698/

Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer

الانترنت

مواد مشابهة